Relay Therapeutics
company in Cambridge, United States
RLAY Nasdaq
SEC CIK 1812364
Follow Relay Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$81.7M
−10.2% vs same quarter last year
EPS, diluted
−$0.37
+14% vs same quarter last year
Operating cash flow
−$63.9M
−2.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $15.4M | −$276.5M |
| FY24 | $10M | −$337.7M |
| FY23 | $25.5M | −$342M |
| FY22 | $1.4M | −$290.5M |
| FY21 | $3M | −$363.9M |
| FY20 | $82.7M | −$52.4M |
| FY19 | - | −$75.3M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1971.6% | −1800.6% |
| FY24 | −3722.1% | −3374.7% |
| FY23 | −1460.1% | −1338.7% |
| FY22 | −21670.9% | −21036.1% |
| FY21 | −12040.2% | −12012.9% |
| FY20 | −67.5% | −63.4% |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$235.9M |
| FY24 | −$251.1M |
| FY23 | −$304.4M |
| FY22 | −$238.6M |
| FY21 | −$77.9M |
| FY20 | −$104.4M |
| FY19 | −$74.1M |
| FY18 | - |
- Relay Therapeutics
- Healthcare median
Show the numbers
| Year | Relay Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −1800.6% | −30.6% |
| FY24 | −3374.7% | −47% |
| FY23 | −1338.7% | −58% |
| FY22 | −21036.1% | −80.4% |
| FY21 | −12012.9% | −71.8% |
| FY20 | −63.4% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |